Exemplifying the Screening Power of Mass Spectrometry Imaging over Label-Based Technologies for Simultaneous Monitoring of Drug and Metabolite Distributions in Tissue Sections

Journal of Biomolecular Screening

Volumn 21, Issue 2, 2016, Pages 187-193

  Goodwin, Richard J A ^a   Nilsson, Anna ^b   Mackay, C Logan ^c   Swales, John G ^a   Johansson, Maria K ^d   Billger, Martin ^d   Andrén, Per E ^b   Iverson, Suzanne L ^d  

^a ASTRAZENECA   (United Kingdom)

^b UPPSALA UNIVERSITY   (Sweden)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

^d ASTRAZENECA R AND D   (Sweden)

Author keywords

label free; mass spectrometry imaging; screening

Indexed keywords

AZD 2820; CARBON 14; CYCLOPEPTIDE; DRUG METABOLITE; UNCLASSIFIED DRUG; DRUG; PEPTIDE;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYCLOTRON; DRUG DISTRIBUTION; DRUG MONITORING; IMAGING; MASS SPECTROMETRY; MOUSE; NONHUMAN; OPTICAL RESOLUTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SCREENING; TISSUE SECTION; WHOLE BODY AUTORADIOGRAPHY; ANIMAL; AUTORADIOGRAPHY; BLOOD BRAIN BARRIER; C57BL MOUSE; DIAGNOSTIC IMAGING; DRUG DEVELOPMENT; MALE; MATRIX-ASSISTED LASER DESORPTION-IONIZATION MASS SPECTROMETRY; METABOLISM; NEOPLASM; PROCEDURES;

ANIMALS; AUTORADIOGRAPHY; BLOOD-BRAIN BARRIER; DIAGNOSTIC IMAGING; DRUG DISCOVERY; MALE; MICE, INBRED C57BL; NEOPLASMS; PEPTIDES; PHARMACEUTICAL PREPARATIONS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 84954516212     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057115623740     Document Type: Article

References (23)

1. Drexler D. M., Tannehill-Gregg S. H., Wang L., et al. Utility of Quantitative Whole-Body Autoradiography (QWBA) and Imaging Mass Spectrometry (IMS) by Matrix-Assisted Laser Desorption/Ionization (MALDI) in the Assessment of Ocular Distribution of Drugs. J. Pharmacol. Toxicol. Methods 2011, 63, 205-208.
2. Rönquist-Nii Y., Edlund P. O., Determination of Corticosteroids in Tissue Samples by Liquid Chromatography-Tandem Mass Spectrometry. J. Pharm. Biomed. Anal. 2005, 37, 341-350.
3. d'Argy R., Sundwall A., Quantitative Whole-Body Radioluminography-Future Strategy for Balance and Tissue Distribution Studies. Regul. Toxicol. Pharmacol. 2000, 31, S57-S62.
4. Solon E. G., Autoradiography: High-Resolution Molecular Imaging in Pharmaceutical Discovery and Development. Exp. Opin. Drug Discov. 2007, 2, 503-514.
5. Caprioli R. M., Farmer T. B., Gile J., Molecular Imaging of Biological Samples: Localization of Peptides and Proteins Using MALDI-TOF MS. Anal. Chem. 1997, 69, 4751-4760.
6. Reyzer M. L., Hsieh Y., Ng K., et al. Direct Analysis of Drug Candidates in Tissue by Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry. J. Mass Spectrom. 2003, 38, 1081-1092.
7. Nilsson A., Goodwin R. J. A., Shariatgorji M., et al. Mass Spectrometry Imaging in Drug Development. Anal. Chem. 2015, 87, 1437-1455.
8. Cohen L. H., Gusev A. I., Small Molecule Analysis by MALDI Mass Spectrometry. Anal. Bioanal. Chem. 2002, 373, 571-586.
9. Wiseman J. M., Ifa D. R., Zhu Y., et al. Desorption Electrospray Ionization Mass Spectrometry: Imaging Drugs and Metabolites in Tissues. Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 18120-18125.
10. Takáts Z., Wiseman J. M., Gologan B., et al. Mass Spectrometry Sampling under Ambient Conditions with Desorption Electrospray Ionization. Science 2004, 306, 471-473.
11. Passarelli M. K., Newman C. F., Marshall P. S., et al. Single-Cell Analysis: Visualizing Pharmaceutical and Metabolite Uptake in Cells with Label-Free 3D Mass Spectrometry Imaging. Anal. Chem. 2015, 87, 6696-6702.
12. Candy J. M., Oakley A. E., Mountfort S. A., et al. The Imaging and Quantification of Aluminum in the Human Brain Using Dynamic Secondary Ion Mass-Spectrometry (Sims). Biol. Cell. 1992, 74, 109-118.
13. Goodwin R. J. A., Sample Preparation for Mass Spectrometry Imaging: Small Mistakes Can Lead to Big Consequences. J. Proteomics 2012, 75, 4893-4911.
14. Weaver E. M., Hummon A. B., Imaging Mass Spectrometry: From Tissue Sections to Cell Cultures. Adv. Drug Delivery Rev. 2013, 65, 1039-1055.
15. Cobice D. F., Goodwin R. J. A., Andren P. E., et al. Future Technology Insight: Mass Spectrometry Imaging as a Tool in Drug Research and Development. Br. J. Pharmacol. 2015, 172, 3266-3283.
16. Amstalden van Hove E. R., Smith D. F., Heeren R. M. A., A Concise Review of Mass Spectrometry Imaging. J. Chromatogr. A 2010, 1217, 3946-3954.
17. Goodwin R. J., Mackay C. L., Nilsson A., et al. Qualitative and Quantitative MALDI Imaging of the Positron Emission Tomography Ligands Raclopride (a D2 Dopamine Antagonist) and SCH 23390 (a D1 Dopamine Antagonist) in Rat Brain Tissue Sections Using a Solvent-Free Dry Matrix Application Method. Anal. Chem. 2011, 83, 9694-9701.
18. Seeley E. H., Oppenheimer S. R., Mi D., Chaurand P., et al. Enhancement of Protein Sensitivity for MALDI Imaging Mass Spectrometry after Chemical Treatment of Tissue Sections. J. Am. Soc. Mass Spectrom. 2008, 19, 1069-1077.
19. Shariatgorji M., Källback P., Gustavsson L., et al. Controlled-pH Tissue Cleanup Protocol for Signal Enhancement of Small Molecule Drugs Analyzed by MALDI-MS Imaging. Anal. Chem. 2012, 84, 4603-4607.
20. Amstalden van Hove E., Smith D., Fornai L., et al. An Alternative Paper Based Tissue Washing Method for Mass Spectrometry Imaging: Localized Washing and Fragile Tissue Analysis. J. Am. Soc. Mass Spectrom. 2011, 22, 1885-1890.
21. Barry J. A., Groseclose M. R., Robichaud G., et al. Assessing Drug and Metabolite Detection in Liver Tissue by UV-MALDI and IR-MALDESI Mass Spectrometry Imaging Coupled to FT-ICR MS. Int. J. Mass Spectrom. 2015, 377, 448-455.
22. Sun N., Ly A., Neding S., et al. High-Resolution Metabolite Imaging of Light and Dark Treated Retina Using MALDI-FTICR Mass Spectrometry. Proteomics 2014, 14, 913-923.
23. Solon E. G., Schweitzer A., Stoeckli M., et al. Autoradiography, MALDI-MS, and SIMS-MS Imaging in Pharmaceutical Discovery and Development. AAPS J. 2009, 12, 11-26.